Using EvaluatePharma data, Vantage has described how big pharma R&D spending has shifted, showed how internally discovered novel medicines account for a growing…
In 2018 more than a quarter of medtech funding came from rounds in which corporate VCs took part.
The CAR-T company cancels its Nasdaq IPO after securing more in a Novartis-led private financing.
Venture funding drops again, but there’s no need to panic yet.
The J&J-Auris tie-up will yield a huge return for investors who went in big.
Funds backed by drugmakers remain visible contributors to the venture world, but several of the big corporate names seem to have reined in spending.
Transcatheter mitral valve replacement is wrenching the spotlight away from the repair devices that grabbed the headlines last summer.
Venture capital firms invested a record $16.8bn in private drug developers globally in 2018, but signs of a cooling are clear.
Investors swerve traditional medical devices in favour of artificial intelligence-enabled diagnostics.